CN1146712A - 哺乳动物疾病的成肌细胞治疗方法 - Google Patents
哺乳动物疾病的成肌细胞治疗方法 Download PDFInfo
- Publication number
- CN1146712A CN1146712A CN95192528A CN95192528A CN1146712A CN 1146712 A CN1146712 A CN 1146712A CN 95192528 A CN95192528 A CN 95192528A CN 95192528 A CN95192528 A CN 95192528A CN 1146712 A CN1146712 A CN 1146712A
- Authority
- CN
- China
- Prior art keywords
- cell
- sarcoblast
- muscle
- normal
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 32
- 201000010099 disease Diseases 0.000 title claims abstract description 27
- 210000003098 myoblast Anatomy 0.000 title abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 161
- 238000000034 method Methods 0.000 claims abstract description 59
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 49
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 230000003412 degenerative effect Effects 0.000 claims abstract description 11
- 238000010361 transduction Methods 0.000 claims abstract description 8
- 230000026683 transduction Effects 0.000 claims abstract description 8
- 210000000056 organ Anatomy 0.000 claims abstract description 7
- 210000003205 muscle Anatomy 0.000 claims description 121
- 239000000835 fiber Substances 0.000 claims description 53
- 238000012546 transfer Methods 0.000 claims description 26
- 230000008569 process Effects 0.000 claims description 18
- 210000001519 tissue Anatomy 0.000 claims description 16
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 15
- 210000001161 mammalian embryo Anatomy 0.000 claims description 13
- 210000000107 myocyte Anatomy 0.000 claims description 13
- 238000002054 transplantation Methods 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 230000004720 fertilization Effects 0.000 claims description 9
- 210000004165 myocardium Anatomy 0.000 claims description 8
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 7
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 7
- 210000001109 blastomere Anatomy 0.000 claims description 7
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 238000004113 cell culture Methods 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 238000010353 genetic engineering Methods 0.000 claims description 6
- 231100000518 lethal Toxicity 0.000 claims description 6
- 230000001665 lethal effect Effects 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 238000001574 biopsy Methods 0.000 claims description 5
- 239000003018 immunosuppressive agent Substances 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 210000002027 skeletal muscle Anatomy 0.000 claims description 5
- 102000002322 Egg Proteins Human genes 0.000 claims description 4
- 108010000912 Egg Proteins Proteins 0.000 claims description 4
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 4
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 4
- 239000000854 Human Growth Hormone Substances 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 210000001789 adipocyte Anatomy 0.000 claims description 4
- 230000002238 attenuated effect Effects 0.000 claims description 4
- 235000013601 eggs Nutrition 0.000 claims description 4
- 210000004681 ovum Anatomy 0.000 claims description 4
- 208000033040 Somatoform disorder pregnancy Diseases 0.000 claims description 3
- 210000002459 blastocyst Anatomy 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 230000005611 electricity Effects 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 230000008521 reorganization Effects 0.000 claims description 3
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 230000008355 cartilage degradation Effects 0.000 claims description 2
- 230000002380 cytological effect Effects 0.000 claims description 2
- 208000009429 hemophilia B Diseases 0.000 claims description 2
- 208000018360 neuromuscular disease Diseases 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 210000002460 smooth muscle Anatomy 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims 2
- 102000006771 Gonadotropins Human genes 0.000 claims 1
- 108010086677 Gonadotropins Proteins 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 210000001612 chondrocyte Anatomy 0.000 claims 1
- 239000002622 gonadotropin Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 230000008771 sex reversal Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 230000002068 genetic effect Effects 0.000 abstract description 9
- 230000001114 myogenic effect Effects 0.000 abstract description 9
- 230000008439 repair process Effects 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000007910 cell fusion Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 230000000704 physical effect Effects 0.000 abstract 1
- 208000030212 nutrition disease Diseases 0.000 description 38
- 238000002347 injection Methods 0.000 description 34
- 239000007924 injection Substances 0.000 description 34
- 208000019180 nutritional disease Diseases 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 238000011160 research Methods 0.000 description 18
- 201000001441 melanoma Diseases 0.000 description 17
- 230000004927 fusion Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 201000006938 muscular dystrophy Diseases 0.000 description 12
- 230000006870 function Effects 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 210000005036 nerve Anatomy 0.000 description 9
- 238000002659 cell therapy Methods 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 7
- 208000026350 Inborn Genetic disease Diseases 0.000 description 6
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
- 102000013275 Somatomedins Human genes 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 208000024556 Mendelian disease Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000007850 degeneration Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- DVGHHMFBFOTGLM-UHFFFAOYSA-L fluorogold Chemical compound F[Au][Au]F DVGHHMFBFOTGLM-UHFFFAOYSA-L 0.000 description 5
- 230000009395 genetic defect Effects 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 5
- 229960004618 prednisone Drugs 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 229930105110 Cyclosporin A Natural products 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 4
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 4
- 208000028782 Hereditary disease Diseases 0.000 description 4
- 101710172711 Structural protein Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 229930182912 cyclosporin Natural products 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 3
- 102000055025 Adenosine deaminases Human genes 0.000 description 3
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- 238000001964 muscle biopsy Methods 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 230000004220 muscle function Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000000518 sarcolemma Anatomy 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000557626 Corvus corax Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 2
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 2
- 241000283986 Lepus Species 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000001217 buttock Anatomy 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000002559 cytogenic effect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000012637 gene transfection Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000297 inotrophic effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- CLVOYFRAZKMSPF-UHFFFAOYSA-N n,n-dibutyl-4-chlorobenzenesulfonamide Chemical compound CCCCN(CCCC)S(=O)(=O)C1=CC=C(Cl)C=C1 CLVOYFRAZKMSPF-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 210000002363 skeletal muscle cell Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- NHUFMXNVSAWNTO-OJUPNBFJSA-N (3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O.OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O NHUFMXNVSAWNTO-OJUPNBFJSA-N 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 208000029323 Congenital myotonia Diseases 0.000 description 1
- 241000252095 Congridae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101150060155 Dcc gene Proteins 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000010316 Myotonia congenita Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 241000692885 Nymphalis antiopa Species 0.000 description 1
- 241001561899 Otomys Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 101150027964 ada gene Proteins 0.000 description 1
- OFBHPPMPBOJXRT-UHFFFAOYSA-N adenylosuccinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C2=NC=NC(NC(CC(O)=O)C(O)=O)=C2N=C1 OFBHPPMPBOJXRT-UHFFFAOYSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 238000011130 autologous cell therapy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000001047 desmosome Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000011089 mechanical engineering Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000009340 myotonic dystrophy type 1 Diseases 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000005424 photoluminescence Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/90—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (19)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35494494A | 1994-12-13 | 1994-12-13 | |
US08/354,944 | 1994-12-13 | ||
US47737795A | 1995-06-07 | 1995-06-07 | |
US08/477,377 | 1995-06-07 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA031015883A Division CN1477190A (zh) | 1994-12-13 | 1995-12-13 | 控制细胞融合的方法和相关组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1146712A true CN1146712A (zh) | 1997-04-02 |
CN1127343C CN1127343C (zh) | 2003-11-12 |
Family
ID=26998623
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95192528A Expired - Fee Related CN1127343C (zh) | 1994-12-13 | 1995-12-13 | 治疗哺乳动物疾病的成肌细胞组合物 |
CNA031015883A Pending CN1477190A (zh) | 1994-12-13 | 1995-12-13 | 控制细胞融合的方法和相关组合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA031015883A Pending CN1477190A (zh) | 1994-12-13 | 1995-12-13 | 控制细胞融合的方法和相关组合物 |
Country Status (7)
Country | Link |
---|---|
US (3) | US6261832B1 (zh) |
EP (2) | EP1407788A2 (zh) |
CN (2) | CN1127343C (zh) |
AU (1) | AU4597696A (zh) |
CA (1) | CA2183167A1 (zh) |
SG (3) | SG99846A1 (zh) |
WO (1) | WO1996018303A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103550784A (zh) * | 2013-08-16 | 2014-02-05 | 彼得·K·罗 | 通过人成肌细胞移植的疾病预防和缓解 |
CN107208049A (zh) * | 2014-09-18 | 2017-09-26 | 财团法人卫生研究院 | 祖细胞、其制备方法及其应用 |
CN107920503A (zh) * | 2015-06-11 | 2018-04-17 | 伊利诺伊大学理事会 | 肌营养不良症嵌合细胞和治疗肌营养不良症的方法 |
CN107998150A (zh) * | 2016-10-27 | 2018-05-08 | 彼德·盖·罗 | 包含用于通过植入抑制肿瘤生长和预防癌细胞转移的成肌细胞的组合物 |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869041A (en) * | 1996-01-12 | 1999-02-09 | The Miriam Hospital | Delivery of bioactive compounds to an organism |
US6321109B2 (en) | 1996-02-15 | 2001-11-20 | Biosense, Inc. | Catheter based surgery |
CA2225185A1 (en) * | 1997-08-11 | 1999-02-11 | Peter K. Law | Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities |
EP1563866B1 (en) | 1998-02-05 | 2007-10-03 | Biosense Webster, Inc. | Intracardiac drug delivery |
US6866842B1 (en) | 1998-05-01 | 2005-03-15 | University Of Pittsburgh | Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction |
DE69936785D1 (de) * | 1998-05-01 | 2007-09-20 | Univ Pittsburgh | Zellvermittelte genverabreichung durch verwendung von aus muskeln derivierten zellen zur behandlung der knochen-verwandten verletzung oder störung |
US7115417B1 (en) | 1998-05-01 | 2006-10-03 | Chancellor Michael B | Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof |
JP2003505475A (ja) | 1999-07-23 | 2003-02-12 | ダイアクリン インク | 筋細胞、及び心臓修復におけるそれらの利用 |
US20030113301A1 (en) * | 1999-07-23 | 2003-06-19 | Albert Edge | Muscle cells and their use in cardiac repair |
ES2288946T3 (es) | 2000-04-14 | 2008-02-01 | University Of Pittsburgh | Aumento y abultamiento de tejido blando y hueso utilizando celulas progenitoras derivadas de musculo, sus composiciones y tratamientos. |
ATE345158T1 (de) * | 2000-09-12 | 2006-12-15 | Peter K Law | Katheter für den myogenen zelltransfer |
AU2007202290B2 (en) * | 2000-09-12 | 2011-11-03 | Law, Peter K | Myogenic cell transfer catheter and method |
WO2002067867A2 (en) | 2001-02-23 | 2002-09-06 | The University Of Pittsburgh | Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair |
US6681773B2 (en) * | 2001-02-28 | 2004-01-27 | Chase Medical, Inc. | Kit and method for use during ventricular restoration |
US20020133227A1 (en) * | 2001-02-28 | 2002-09-19 | Gregory Murphy | Ventricular restoration patch apparatus and method of use |
US7485088B2 (en) | 2001-09-05 | 2009-02-03 | Chase Medical L.P. | Method and device for percutaneous surgical ventricular repair |
EP1453382A4 (en) | 2001-11-08 | 2005-05-18 | Univ California | METHODS AND COMPOSITIONS FOR CORRECTION OF CARDIAC CONDUCTION DISORDERS |
EP1497410A4 (en) * | 2002-04-01 | 2005-05-25 | Peter K Law | CELL TRANSPLANTATION FOR CARDIAC REGENERATION |
US6932804B2 (en) * | 2003-01-21 | 2005-08-23 | The Regents Of The University Of California | System and method for forming a non-ablative cardiac conduction block |
US20040002740A1 (en) * | 2002-05-08 | 2004-01-01 | The Regents Of The University Of California | System and method for forming a non-ablative cardiac conduction block |
AU2003234520A1 (en) * | 2002-05-08 | 2003-11-11 | The Regents Of The University Of California | Methods and compositions for correction of cardiac conduction disturbances |
US20040106896A1 (en) * | 2002-11-29 | 2004-06-03 | The Regents Of The University Of California | System and method for forming a non-ablative cardiac conduction block |
JP2005534430A (ja) * | 2002-08-06 | 2005-11-17 | ジェンベック, インコーポレイテッド | 改良された注射システム |
WO2004017972A1 (en) * | 2002-08-23 | 2004-03-04 | Law Peter K | Biologic skin repair and enhancement |
US7317950B2 (en) * | 2002-11-16 | 2008-01-08 | The Regents Of The University Of California | Cardiac stimulation system with delivery of conductive agent |
US20040158289A1 (en) * | 2002-11-30 | 2004-08-12 | Girouard Steven D. | Method and apparatus for cell and electrical therapy of living tissue |
US7627373B2 (en) * | 2002-11-30 | 2009-12-01 | Cardiac Pacemakers, Inc. | Method and apparatus for cell and electrical therapy of living tissue |
US9617516B2 (en) | 2003-04-25 | 2017-04-11 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Muscle-derived cells (MDCs) for promoting and enhancing nerve repair and regeneration |
DE10339905B4 (de) * | 2003-08-29 | 2009-04-23 | Kist-Europe Forschungsgesellschaft Mbh | Implantierbarer Mikrozellprozessor zur Krankheitsbehandlung |
US7840263B2 (en) * | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
SG137871A1 (en) | 2004-06-01 | 2007-12-28 | In Motion Investment Ltd | In vitro techniques for use with stem cells |
US7764995B2 (en) | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
US7828711B2 (en) * | 2004-08-16 | 2010-11-09 | Cardiac Pacemakers, Inc. | Method and apparatus for modulating cellular growth and regeneration using ventricular assist device |
US7981065B2 (en) | 2004-12-20 | 2011-07-19 | Cardiac Pacemakers, Inc. | Lead electrode incorporating extracellular matrix |
US8060219B2 (en) * | 2004-12-20 | 2011-11-15 | Cardiac Pacemakers, Inc. | Epicardial patch including isolated extracellular matrix with pacing electrodes |
US20060180187A1 (en) * | 2005-02-14 | 2006-08-17 | Squeegit, Inc. | Window cleaning apparatus |
US20070059288A1 (en) * | 2005-03-31 | 2007-03-15 | Dinsmore Jonathan H | Treatment for heart disease |
AU2006244197A1 (en) | 2005-05-09 | 2006-11-16 | Mytogen, Inc. | Cellular cardiomyoplasty as supportive therapy in patients with heart disease |
US20110206643A1 (en) * | 2005-06-02 | 2011-08-25 | In Motion Investment, Ltd. | Automated Cell Therapy System |
TW200734462A (en) | 2006-03-08 | 2007-09-16 | In Motion Invest Ltd | Regulating stem cells |
EP2118271B1 (en) | 2007-01-11 | 2018-04-18 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Muscle derived cells for the treatment of urinary tract pathologies and methods of making and using the same |
FR2931485B1 (fr) * | 2008-05-23 | 2011-06-17 | Centre Nat Rech Scient | Vaccin antitumoral comprenant des cellules tumorales modifiees |
US9199003B2 (en) | 2008-08-18 | 2015-12-01 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof |
US20100233138A1 (en) * | 2008-11-07 | 2010-09-16 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Vocal Cord Augmentation Utilizing Muscle-Derived Progenitor Compositions, and Treatments Thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS51151384A (en) * | 1975-06-20 | 1976-12-25 | Olympus Optical Co Ltd | Process for cultivating organic tissue or cells automatically |
US4228243A (en) * | 1978-07-13 | 1980-10-14 | Toray Industries, Inc. | Cell culture propagation apparatus |
US4500544A (en) | 1981-09-10 | 1985-02-19 | Chugai Seiyaku Kabushiki Kaisha | Ascochlorin derivatives, and pharmaceutical composition containing the same |
JPS5948614B2 (ja) * | 1982-03-30 | 1984-11-28 | ヤマザキナビスコ株式会社 | ポテトフレ−クを主原料としたスナツク菓子の製造方法 |
US4663292A (en) * | 1984-12-21 | 1987-05-05 | Wong Daniel T | High-voltage biological macromolecule transfer and cell fusion system |
US5130141A (en) * | 1988-05-24 | 1992-07-14 | Law Peter K | Compositions for and methods of treating muscle degeneration and weakness |
JP2993982B2 (ja) * | 1988-10-21 | 1999-12-27 | モレキユラー デヴアイシズ コーポレイシヨン | 生細胞に対する細胞作用剤の効果を検出するための方法及び装置 |
US5240854A (en) * | 1989-06-05 | 1993-08-31 | Berry Eric S | Continuous high-density cell culture system |
US5139481A (en) * | 1991-08-07 | 1992-08-18 | The General Hospital Corporation | Treatment for type II diabetes |
CA2102519A1 (en) * | 1992-03-04 | 1993-09-05 | Jon A. Wolff | Method of delivering therapeutic substances to the brain |
US5602301A (en) * | 1993-11-16 | 1997-02-11 | Indiana University Foundation | Non-human mammal having a graft and methods of delivering protein to myocardial tissue |
US5512480A (en) * | 1994-03-11 | 1996-04-30 | Baxter International Inc. | Flow-through bioreactor with grooves for cell retention |
US5919449A (en) * | 1995-05-30 | 1999-07-06 | Diacrin, Inc. | Porcine cardiomyocytes and their use in treatment of insufficient cardiac function |
-
1995
- 1995-12-13 CN CN95192528A patent/CN1127343C/zh not_active Expired - Fee Related
- 1995-12-13 WO PCT/US1995/016093 patent/WO1996018303A1/en not_active Application Discontinuation
- 1995-12-13 SG SG9801012A patent/SG99846A1/en unknown
- 1995-12-13 EP EP20040000891 patent/EP1407788A2/en active Pending
- 1995-12-13 EP EP95944088A patent/EP0743820A4/en not_active Withdrawn
- 1995-12-13 SG SG9801014A patent/SG99279A1/en unknown
- 1995-12-13 AU AU45976/96A patent/AU4597696A/en not_active Abandoned
- 1995-12-13 CN CNA031015883A patent/CN1477190A/zh active Pending
- 1995-12-13 SG SG1997004642A patent/SG74036A1/en unknown
- 1995-12-13 CA CA002183167A patent/CA2183167A1/en not_active Abandoned
-
1998
- 1998-01-09 US US09/005,035 patent/US6261832B1/en not_active Expired - Fee Related
- 1998-01-09 US US09/005,034 patent/US7341719B1/en not_active Expired - Lifetime
-
2001
- 2001-05-31 US US09/867,519 patent/US20020031501A1/en not_active Abandoned
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103550784A (zh) * | 2013-08-16 | 2014-02-05 | 彼得·K·罗 | 通过人成肌细胞移植的疾病预防和缓解 |
CN107648267A (zh) * | 2013-08-16 | 2018-02-02 | 彼得·K·罗 | 通过人成肌细胞移植的疾病预防和缓解 |
CN108042571A (zh) * | 2013-08-16 | 2018-05-18 | 彼得·K·罗 | 通过人成肌细胞移植的疾病预防和缓解 |
CN107208049A (zh) * | 2014-09-18 | 2017-09-26 | 财团法人卫生研究院 | 祖细胞、其制备方法及其应用 |
CN107920503A (zh) * | 2015-06-11 | 2018-04-17 | 伊利诺伊大学理事会 | 肌营养不良症嵌合细胞和治疗肌营养不良症的方法 |
CN107998150A (zh) * | 2016-10-27 | 2018-05-08 | 彼德·盖·罗 | 包含用于通过植入抑制肿瘤生长和预防癌细胞转移的成肌细胞的组合物 |
Also Published As
Publication number | Publication date |
---|---|
US6261832B1 (en) | 2001-07-17 |
US7341719B1 (en) | 2008-03-11 |
SG74036A1 (en) | 2000-07-18 |
EP1407788A2 (en) | 2004-04-14 |
AU4597696A (en) | 1996-07-03 |
EP0743820A4 (en) | 1997-06-11 |
CN1127343C (zh) | 2003-11-12 |
CA2183167A1 (en) | 1996-06-20 |
US20020031501A1 (en) | 2002-03-14 |
EP0743820A1 (en) | 1996-11-27 |
CN1477190A (zh) | 2004-02-25 |
SG99846A1 (en) | 2003-11-27 |
SG99279A1 (en) | 2003-10-27 |
WO1996018303A1 (en) | 1996-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1127343C (zh) | 治疗哺乳动物疾病的成肌细胞组合物 | |
TWI278517B (en) | Methods and compositions for the differentiation of human preadipocytes into adipocytes | |
Deasy et al. | Long-term self-renewal of postnatal muscle-derived stem cells | |
US20030161818A1 (en) | Cultures, products and methods using stem cells | |
US20050014255A1 (en) | Stem cells for clinical and commercial uses | |
CN101878297A (zh) | 用于间质干细胞优化扩增和移植的方法与组合物 | |
US20060247195A1 (en) | Method of altering cell properties by administering rna | |
CN103930542A (zh) | 棕色脂肪细胞组合物及方法 | |
CN1533431A (zh) | 细胞移植的方法和试剂 | |
US10870830B2 (en) | Method for culturing differentiation-promoting and -sustaining spheroid form of tonsil-derived stem cells | |
KR20030088023A (ko) | 미리 선별된 면역형 및(또는) 유전자형을 갖는 동형접합성간세포 군집의 제조 방법, 그로부터 유래된 이식에 적합한세포, 및 이들을 사용하는 재료 및 방법 | |
CN103562377B (zh) | 引入了肝细胞生长因子基因和具有碱性螺旋-环-螺旋基序的神经源性转录因子基因的成人干细胞系及其用途 | |
JP2002501899A (ja) | IPGsとIPG類似体の神経栄養特性 | |
KR20150091519A (ko) | 다계열 분화능 세포 생성 방법 | |
CN104755610A (zh) | 脂肪组织细胞 | |
WO1998057663A1 (en) | Neural transplantation for treating neurological disease | |
Seelbinder et al. | Intra-nuclear tensile strain mediates reorganization of epigenetically marked chromatin during cardiac development and disease | |
AU748997B2 (en) | Myoblast therapy for mammalian diseases | |
Rastgar et al. | Spontaneously contracting cell aggregates derived from grass carp heart as a promising tool in in vitro heart research | |
US20120141984A1 (en) | Methods of isolating stem cells | |
KR20130102506A (ko) | 성숙 낭성 기형종 유래 세포 및 조직의 용도 | |
EP4071238A1 (en) | Cardiomyocyte aggregate production technique improving survival rate under cryopreservation and hypoxic conditions | |
EP4282423A1 (en) | Pharmaceutical composition for prevention or treatment of inflammatory disease or pain, comprising mesenchymal stem cells expressing ptx-3, timp1 and bdnf as active ingredient | |
CA2527700A1 (en) | Stem cells for clinical and commercial uses | |
CN118185865A (zh) | 一种tfam条件性敲除的细胞系、心肌细胞及其构建方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WUHAN PENGLAI SARCOBLAST BIOENGINEERING RESEARCH I Free format text: FORMER OWNER: LAW PETER K. Effective date: 20110328 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: TENNESSEE, THE USA TO: 430074 ROOM 601, BUILDING 8, GUANGGU VENTURE STREET,SBI, DONGHU DEVELOPMENT ZONE, WUHAN CITY, HUBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20110328 Address after: 430074, room 8, building 601, SBI Pioneer Street, East Lake Development Zone, Wuhan, Hubei, Optics Valley Patentee after: Penglai Wuhan myoblast Biomedical Engineering Research Institute Co Ltd Address before: Tennessee Patentee before: Peter K. Law |
|
ASS | Succession or assignment of patent right |
Owner name: CELL THERAPY INSTITUTE WUHAN CO., LTD. Free format text: FORMER OWNER: WUHAN PENGLAI MYOBLAST BIOMEDICAL ENGINEERING RESEARCH INSTITUTE CO., LTD. Effective date: 20111111 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20111111 Address after: 430074, room 8, building 601, SBI Pioneer Street, East Lake Development Zone, Wuhan, Hubei, Optics Valley Patentee after: Abrikosoff rogie Medical Research Institute Wuhan Co. Ltd. Address before: 430074, room 8, building 601, SBI Pioneer Street, East Lake Development Zone, Wuhan, Hubei, Optics Valley Patentee before: Penglai Wuhan myoblast Biomedical Engineering Research Institute Co Ltd |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20031112 Termination date: 20131213 |